ObjectiveStatins stimulate transcription of proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of the low-density lipoprotein receptor, thus blunting the cholesterol-lowering effects of statin treatment. Although there is interindividual variation in PCSK9 statin response, little is known about ancestral and other genetic factors that could contribute to this variation.MethodsWe measured plasma PCSK9 levels before and after 6 weeks of treatment with 40 mg/day simvastatin in 901 participants of the Cholesterol and Pharmacogenetics clinical trial and tested phenotypic and genetic factors for correlation with PCSK9 statin response.ResultsStatin-induced changes in plasma low-density lipoprotein cholesterol, total choles...
Selected missense mutations in the proprotein convertase subtilisin/kexin type 9 serine protease gen...
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipop...
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein converta...
ObjectiveStatins stimulate transcription of proprotein convertase subtilisin/kexin type 9 (PCSK9), a...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolis...
Variants of the secreted glycoprotein, proprotein convertase subtilisin/kexin 9 (PCSK9), associate w...
Objective: To study the relation between circulating proprotein convertase subtilisin kexin type 9 (...
Only a year or so ago we thought we understood the primary determinants of low-density lipoprotein, ...
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a protein involved in LDL-cholesterol ...
We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...
Background We characterised the phenotypic consequence of genetic variation at the P...
Selected missense mutations in the proprotein convertase subtilisin/kexin type 9 serine protease gen...
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipop...
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein converta...
ObjectiveStatins stimulate transcription of proprotein convertase subtilisin/kexin type 9 (PCSK9), a...
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism,...
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolis...
Variants of the secreted glycoprotein, proprotein convertase subtilisin/kexin 9 (PCSK9), associate w...
Objective: To study the relation between circulating proprotein convertase subtilisin kexin type 9 (...
Only a year or so ago we thought we understood the primary determinants of low-density lipoprotein, ...
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a protein involved in LDL-cholesterol ...
We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...
Background We characterised the phenotypic consequence of genetic variation at the P...
Selected missense mutations in the proprotein convertase subtilisin/kexin type 9 serine protease gen...
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipop...
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein converta...